The Journal of infectious diseases · 2025
Molecular Characterization of Respiratory Syncytial Virus Infections in Elderly Patients During the 2023-2024 Season in the Era of Nirsevimab Introduction.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Caillault Amandine, Softic Laurent, Bay Pierre, Ly Arnaud, Soulier Alexandre, Melica Giovanna, Rodriguez Christophe, de Prost Nicolas, Pawlotsky Jean-Michel, Fourati Slim
Аннотация
Respiratory syncytial virus (RSV) can cause severe infections in elderly individuals. Nirsevimab is a novel prophylactic monoclonal antibody, widely used in infants in France during the 2023-2024 season. It may select for resistant RSV variants that, if transmitted in the community, could compromise vaccine efficacy in the elderly. In this study, we analyzed RSV full-length genomes (68% RSV-A, 32% RSV-B) from 125 patients aged >60 years during the 2023-2024 season. Genetic diversity of RSV-F site Ø was low, with no resistance-associated substitutions (RASs) detected. While no RASs were identified, ongoing monitoring is essential to prevent the emergence of resistant variants that could affect vaccine efficacy in the elderly.